Business Overview
Amarin Corporation plc (NASDAQ: AMRN) is a global pharmaceutical company dedicated to reducing the cardiovascular disease (CVD) burden for patients and advancing cardiovascular care worldwide. The company owns and supports a global branded product, which is approved by multiple regulatory authorities based on a proven efficacy and safety track record. The company’s commercialization model utilizes a direct sales approach in the United States and an indirect distribution strategy internationally. This international strategy involves a syndicate of well-established partners covering nearly 100 markets worldwide.
VASCEPA capsules were the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) composed solely of the active ingredient icosapent ethyl (IPE). The drug was initially launched in the United States in 2013 as an adjunct therapy to diet for reducing triglyceride levels in adult patients with severe, hypertriglyceridemia. Subsequently, in January 2020, VASCEPA was launched as the first FDA-approved drug for treating studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. Since its launch, VASCEPA has been prescribed more than twenty-five million times and is covered by most major medical insurance plans. Outside the United States, VASCEPA is approved and sold in multiple regions, including Canada, China, Australia, and parts of the Middle East. In Europe, marketing authorization was granted in 2021 under the brand name VAZKEPA , and it is currently approved and sold in several European nations, including Sweden, Finland, England, Spain, and Italy, among others.
Key Financial Performance Highlights
Amarin reported significant improvements in its bottom line for the fourth quarter and full year ended December 31, 2025, driven heavily by its strategic initiatives and refined business model.
Total Net Revenue: Total net revenue for Q4 2025 was $49.2 million, representing a 21% decrease from the $62.3 million reported in Q4 2024. For the full year 2025, total net revenue was $213.6 million, down from $228.6 million in the full year 2024.
Operating Loss and Margin: Operating loss for Q4 2025 narrowed substantially to $(6.3) million, a significant $46.2 million or 88% improvement compared to the operating loss of $(52.5) million in Q4 2024. Operating margin improved to (13)% from (84)% in the prior year’s quarter. For the full year 2025, the operating loss was $(50.1) million compared to $(91.7) million in 2024.
Net Loss: The net loss for Q4 2025 improved by 97% to $(1.2) million, equating to $(0.00)$ per basic and diluted share. This compares favorably to a net loss of $(48.6) million, or $(0.12)$ per share, in Q4 2024. The full year 2025 net loss was $(38.7) million, or $(0.09)$ per share, compared to $(82.1) million, or $(0.20)$ per share, in 2024.
Non-GAAP Adjusted Metrics: Non-GAAP adjusted net income for Q4 2025 was $4.39 million, or $0.01 per diluted share. This marked a recovery from a non-GAAP adjusted net loss of $(8.7) million, or $(0.02)$ per diluted share, in Q4 2024. For the full year 2025, non-GAAP adjusted net income was $16.1 million, or $0.04 per diluted share, compared to $11.7 million, or $0.04 per diluted share, in 2024.
Liquidity and Balance Sheet: The company reported an aggregate cash and investments position of $302.6 million as of December 31, 2025. This reflects an $8.4 million year-over-year increase from $294.2 million as of December 31, 2024, and a sequential increase of $16.0 million from September 30, 2025. Amarin remained entirely debt-free as of the close of 2025. Total assets as of December 31, 2025, were $670.7 million, while total liabilities stood at $211.4 million, leaving total stockholders’ equity at $459.2 million.
Segment-Wise Performance
The revenue profile demonstrated mixed dynamics across regions, heavily influenced by transitional operations and market adjustments.
U.S. Product Revenue: U.S. product revenue, net, was $41.1 million in Q4 2025, a 7% decline from $44.2 million in Q4 2024.
Europe Product Revenue: Product revenue in Europe dropped 42% to $2.3 million in Q4 2025, compared to $4.0 million in the same quarter of the prior year.
Rest-of-World (ROW) Product Revenue: ROW revenues saw the sharpest decline, falling 74% to $3.1 million in Q4 2025, down from $11.9 million in Q4 2024.
Licensing and Royalties: Contrasting with product revenue declines, licensing and royalties increased by 20% to $2.7 million in Q4 2025, up from $2.2 million in Q4 2024.
The overall $13.1 million decrease in Total Net Revenue was primarily attributed to the steep drop in ROW sales, which faced a tough comparable against a $7.8 million stocking order in Q4 2024 related to a market launch preparation. Furthermore, a decline in U.S. net selling price and the transitional effects of shifting European sales activities to Recordati S.p.A. weighed on the top line. Royalty revenue growth was driven by higher in-market sales generated by Amarin’s global partners.
Operational Metrics and Key Drivers
A major driver of the company’s narrowing losses was rigorous cost optimization. Operating expenses in Q4 2025 decreased by 31% to $29.5 million, down from $43.0 million in Q4 2024.
Cost of Goods Sold (COGS): COGS decreased by 64% to $26.1 million from $71.9 million in the prior year’s fourth quarter. The Q4 2024 figure included a significant $36.5 million one-time inventory restructuring charge and a write-off to align supplier agreements with expected demand. Excluding these one-time charges, Q4 2025 COGS declined by 10% ($2.8 million), primarily corresponding to the lower net product sales.
Selling, General, and Administrative (SG&A): SG&A expenses dropped by 46% to $20.1 million in Q4 2025, compared to $37.0 million in Q4 2024. This reduction was primarily an outcome of the Global Restructuring Plan and other cost-saving initiatives.
Research and Development (R&D): R&D expenses remained largely consistent, coming in at $5.4 million for Q4 2025 compared to $6.0 million in Q4 2024.
Restructuring Costs: The company recognized a $4.1 million restructuring charge in Q4 2025, tied to the June 2025 Global Restructuring Plan and the Recordati Licensing Agreement. This plan resulted in the elimination of commercial roles within its European operations. Over the full year 2025, restructuring charges totaled $36.2 million, which aligns with management’s total expectation of $37 to $40 million, with residual charges expected in early 2026.
Operationally, the restructuring initiatives realized $31 million of an expected $70 million in cost savings. These operational realignments accelerated Amarin’s return to positive cash flow in the fourth quarter, occurring ahead of schedule.
Management Commentary and Strategic Updates
Management emphasized the successful execution of operational efficiencies and business model transitions.
Aaron Berg, President and Chief Executive Officer, stated that the financial performance validated both the initial impact and the long-term potential of the company’s re-imagined operating model. Berg highlighted that Amarin enters 2026 from an improved position of market, operational, and financial strength. He noted the maintenance of a leading U.S. market share for VASCEPA and active expansion in Europe through the long-term partnership with Recordati S.p.A., representing a fully partnered international commercial strategy. Management continues to evaluate strategic actions to maximize future shareholder value and options regarding capital management.
Peter Fishman, Chief Financial Officer, reinforced that Q4 performance reflects early success in optimizing operations to create a more efficient platform for long-term growth. He highlighted that the return to positive cash flow has positioned Amarin well to generate positive cash flow for the full year ahead and to deliver on 2026 strategic priorities.
On the scientific front, Amarin supported a total of 45 publications (including abstracts, posters, and manuscripts) in 2025 to further the expansion of the VASCEPA/VAZKEPA body of knowledge.
Notable Risks and Challenges
While Amarin has significantly improved its cost structure, several risks and challenges were explicitly noted regarding its operations and its product profile.
Commercial and Revenue Risks:
A decline in the net selling price in the U.S. negatively impacted total product revenue.
The transition from direct sales in Europe to a fully partnered model with Recordati is ongoing; once completed, European revenues will transition purely to supply shipments rather than direct sales, inherently shifting the revenue composition.
Management outlined that forward-looking statements involve substantial risks regarding the company’s ability to attract additional collaborators and effectively manage strategic collaboration and licensing agreements.
Clinical and Safety Risks:
VASCEPA is strictly contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or its components.
In a double-blind, placebo-controlled trial, VASCEPA was associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization. This incidence was higher in patients with a history of atrial fibrillation or flutter.
VASCEPA was associated with an increased risk of bleeding, with higher incidence among patients taking concomitant antithrombotic medications like aspirin, clopidogrel, or warfarin. Patients taking these alongside VASCEPA require monitoring for bleeding.
It remains unknown if patients with fish or shellfish allergies have an increased risk of allergic reactions to VASCEPA; such patients should discontinue the drug if reactions occur.
The effect of VASCEPA on the risk of pancreatitis in patients with severe hypertriglyceridemia remains undetermined.
The post Equity Research Update: Amarin (AMRN) Reaches Positive Cash Flow Ahead of Schedule Following Global Restructuring first appeared on Alphastreet.
